MX2015014751A - Composiciones y metodos para el tratamiento de la inmunodeficiencia. - Google Patents

Composiciones y metodos para el tratamiento de la inmunodeficiencia.

Info

Publication number
MX2015014751A
MX2015014751A MX2015014751A MX2015014751A MX2015014751A MX 2015014751 A MX2015014751 A MX 2015014751A MX 2015014751 A MX2015014751 A MX 2015014751A MX 2015014751 A MX2015014751 A MX 2015014751A MX 2015014751 A MX2015014751 A MX 2015014751A
Authority
MX
Mexico
Prior art keywords
compositions
methods
treatment
immunodeficiency
prophylaxis
Prior art date
Application number
MX2015014751A
Other languages
English (en)
Other versions
MX370191B (es
Inventor
S Grossman Adam
B Grossman Jerrold
Mond James
A Goldstein Dov
Original Assignee
Adma Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adma Biologics Inc filed Critical Adma Biologics Inc
Publication of MX2015014751A publication Critical patent/MX2015014751A/es
Publication of MX370191B publication Critical patent/MX370191B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1009—Picornaviridae, e.g. hepatitis A virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1242—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1285—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con composiciones y métodos para el tratamiento de la inmunodeficiencia (por ejemplo, enfermedad por inmunodeficiencia primaria). En particular, la invención proporciona composiciones de inmunoglobulina de plasma humano que contienen títulos de anticuerpos seleccionados, específicos para una pluralidad de patógenos respiratorios, métodos de identificación de donadores humanos y muestras de donador para usarse en las composiciones, métodos de preparación de las composiciones, y métodos de utilización de las composiciones (por ejemplo, para la administración profiláctica y/o tratamiento terapéutico (por ejemplo, inmunización pasiva (por ejemplo, profilaxis inmune))).
MX2015014751A 2014-10-28 2015-10-21 Composiciones y su uso en el tratamiento de la inmunodeficiencia. MX370191B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462069589P 2014-10-28 2014-10-28
US14/592,721 US9107906B1 (en) 2014-10-28 2015-01-08 Compositions and methods for the treatment of immunodeficiency
US14/592,727 US9815886B2 (en) 2014-10-28 2015-01-08 Compositions and methods for the treatment of immunodeficiency
US14/790,872 US9714283B2 (en) 2014-10-28 2015-07-02 Compositions and methods for the treatment of immunodeficiency

Publications (2)

Publication Number Publication Date
MX2015014751A true MX2015014751A (es) 2016-10-19
MX370191B MX370191B (es) 2019-12-04

Family

ID=53785845

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014751A MX370191B (es) 2014-10-28 2015-10-21 Composiciones y su uso en el tratamiento de la inmunodeficiencia.

Country Status (11)

Country Link
US (8) US9815886B2 (es)
EP (2) EP4233903A3 (es)
AU (2) AU2015246157B2 (es)
BR (1) BR102015027387A2 (es)
CA (1) CA2910491A1 (es)
HK (1) HK1225397A1 (es)
IL (2) IL242156B (es)
MX (1) MX370191B (es)
RU (1) RU2724058C2 (es)
WO (1) WO2016069693A1 (es)
ZA (1) ZA201707303B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103958544B (zh) * 2011-09-16 2018-04-24 Ucb医药有限公司 针对艰难梭菌的主要外毒素TcdA和TcdB的中和抗体
US9815886B2 (en) * 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
CN105601736B (zh) * 2016-01-28 2019-04-23 哈尔滨派斯菲科生物制药股份有限公司 一种抗呼吸道合胞病毒人免疫球蛋白及其制备方法
CN106119210B (zh) * 2016-07-01 2019-06-11 中国食品药品检定研究院 一种脊髓灰质炎ⅰ型病毒单克隆抗体及其应用
BR112019004929A2 (pt) 2016-09-13 2019-06-04 Allergan Inc composições de toxina clostridial não proteíca
US10259865B2 (en) * 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
US20200246449A1 (en) * 2017-05-03 2020-08-06 Nanobio Corporation Intravenous immunoglobulin compositions specific for respiratory syncytial virus and methods of making and using the same
EP3735273A4 (en) * 2018-01-05 2021-11-17 Network Immunology Inc. COMBINATION OF A PLASMATIC IMMUNOGLOBULIN AND A SPECIFIC ANTIGEN IMMUNOGLOBULIN FOR IMMUNE SYSTEM MODIFICATION AND THE TREATMENT OR PREVENTION OF ALLERGIC DISEASES
EP3810198A4 (en) * 2018-06-21 2022-03-30 Emergent BioSolutions Canada Inc. ZIKA-NEUTRALIZING ANTIBODY COMPOSITIONS AND METHODS OF USE
US20210277093A1 (en) * 2020-03-09 2021-09-09 Adma Biologics, Inc. Immunotherapeutic compositions and methods of production for coronavirus
WO2021195265A1 (en) 2020-03-24 2021-09-30 Ampio Pharmaceuticals, Inc. Methods for treating diseases associated with respiratory viruses
US20230149542A1 (en) * 2020-04-06 2023-05-18 Abbott Laboratories Nutritional formulations for modulating respiratory-induced cytokines
US20220034885A1 (en) * 2020-08-03 2022-02-03 Adma Biologics, Inc. Compositions and methods for determining coronavirus neutralization titers
WO2022060976A1 (en) * 2020-09-17 2022-03-24 The Broad Institute, Inc. Methods for treating infections
CN113943836B (zh) * 2021-11-16 2023-09-22 圣湘生物科技股份有限公司 检测引起呼吸道感染的病原体并鉴定病原体种类的组合物、试剂盒、方法及用途

Family Cites Families (216)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4021540A (en) 1975-07-28 1977-05-03 Ortho Diagnostics Inc. Preparation of a hepatitis B immune globulin and use thereof as a prophylactic material
JPS5341420A (en) 1976-09-29 1978-04-14 Mochida Pharm Co Ltd Immunochemically measuring methoa of hapten
JPS604422B2 (ja) 1976-10-07 1985-02-04 持田製薬株式会社 抗原の定量方法
US4174388A (en) 1977-02-14 1979-11-13 Merck & Co., Inc. Method for preparing hepatitis B immune globulin
US4305870A (en) 1979-01-31 1981-12-15 Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte Intravenous plasma derivatives and their production
JPS55124719A (en) 1979-03-22 1980-09-26 Kowa Co Preparation of immune globulin administrable by intravenous injection
FR2460139A1 (fr) 1979-06-29 1981-01-23 Pasteur Institut Fraction antigenique glycopeptidique vaccinante a tres grande immunogenicite isolee de cultures de germes pathogenes, procedes d'isolement de cette fraction et vaccins contenant ladite fraction
FR2475900A1 (fr) 1980-02-20 1981-08-21 Fabre Sa Pierre Complexe vaccinal contenant un antigene specifique et vaccin le contenant
US4346073A (en) 1980-04-11 1982-08-24 The United States Of America As Represented By The Department Of Health And Human Services Hepatitis B immune globulin used to inactivate hepatitis B virus in injectable biological products
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US5360897A (en) 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4482483A (en) 1983-04-06 1984-11-13 Armour Pharmceutical Company Composition of intravenous immune globulin
US4617379A (en) 1983-06-14 1986-10-14 Miles Laboratories, Inc. High titer cytomegalovirus immune serum globulin
CA1247527A (en) 1983-06-14 1988-12-28 Michael S. Collins High titer pseudomonas immune serum globulin
US4587121A (en) 1983-06-14 1986-05-06 Miles Laboratories, Inc. High titer Pseudomonas immune serum globulin
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
CA1340372C (en) 1984-07-09 1999-02-02 John D. Clements Production of e. coli lt-b enterotoxin subunit
NZ214503A (en) 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
SE8501550L (sv) 1985-03-28 1986-09-29 Almex Ab Sett att kontrollera en biljetts ekthet och biljett for att genomfora settet
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4717564A (en) 1985-11-07 1988-01-05 Miles Laboratories, Inc. High titer varicella-zoster immune globulin for intravenous administration
US4665159A (en) 1985-11-07 1987-05-12 Miles Laboratories, Inc. High titer varicella-zoster immune globulin for intravenous administration
US4717766A (en) 1986-01-27 1988-01-05 Miles Laboratories, Inc. Method of preparing high titer anti-respiratory syncytial virus intravenous immune globulin
US4659563A (en) * 1986-01-27 1987-04-21 Miles Laboratories, Inc. High titer anti-respiratory syncytial virus intravenous immune globulin
US4863730A (en) 1986-03-21 1989-09-05 Cenfold Holdings, S.A. Immunotherapy for AIDS patients
FR2605657A1 (fr) 1986-10-22 1988-04-29 Soletanche Procede pour la realisation d'un pieu dans le sol, machine de forage et dispositif pour la mise en oeuvre de ce procede
ATE109008T1 (de) 1988-02-01 1994-08-15 Praxis Biolog Inc T-zellen-epitope als träger für einen konjugierten impfstoff.
DE68929323T2 (de) 1988-12-16 2002-04-18 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin-mutanten und pneumokokken-impfstoffe daraus
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
DE3904415C1 (es) 1989-02-14 1990-04-26 Intracon Handelsgesellschaft Fuer Industriebedarf M.B.H., 6200 Wiesbaden, De
JPH04506662A (ja) 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
JPH05505181A (ja) 1990-03-02 1993-08-05 アルバータ　リサーチ　カウンシル 改善された免疫原性組成物
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5965141A (en) 1991-02-15 1999-10-12 Uab Research Foundation Epitopic regions of pneumococcal surface protein a
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US5679768A (en) 1991-02-15 1997-10-21 Uab Research Foundation Epitopic regions of pneumococcal surface protein A
DE69226167T2 (de) 1991-02-15 1998-11-12 The Uab Research Foundation, Birmingham, Alabama Strukturgen von pneumokokken-protein
AU668092B2 (en) 1991-04-22 1996-04-26 Massachusetts Health Research Institute, Inc. Process of screening plasma samples for effective antibody titers against respiratory viruses
US5854416A (en) 1991-11-14 1998-12-29 The United States Of America As Represented By The Department Of Health And Human Services Streptococcus pneumoniae 37-KDA surface adhesin a protein and nucleic acids coding therefor
WO1993015758A1 (en) 1992-02-06 1993-08-19 Abbott Laboratories Composition and method of immunization with improved carrier and hapten-carrier vaccines
WO1993015760A1 (en) 1992-02-11 1993-08-19 U.S. Government, As Represented By The Secretary Of The Army Dual carrier immunogenic construct
US5445817A (en) 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
US5891438A (en) 1992-10-30 1999-04-06 The Regents Of The University Of California Method for stimulating production of variable region gene family restricted antibodies through B-cell superantigen vaccination
EP0680337A4 (en) 1993-01-12 1997-07-30 Anthony George Gristina METHODS AND COMPOSITIONS FOR DIRECT APPLICATION WITH HIGH CONCENTRATION OF ANTIBODIES, PRODUCING PASSIVE IMMUNITY.
US5681565A (en) 1993-01-12 1997-10-28 Medical Sciences Research Institute Methods and compositions for passive immunotherapy
ES2231770T3 (es) 1993-03-05 2005-05-16 Wyeth Holdings Corporation Nuevos plasmidos para la produccion de proteina crm y toxina difterica.
CA2116261A1 (en) 1993-04-20 1994-10-21 David E. Briles Epitopic regions of pneumococcal surface protein a
US5455032A (en) 1993-07-29 1995-10-03 The United States Of America As Represented By The Department Of Health And Human Services Use of phosphocholine hapten conjugates in vaccines
JP3828145B2 (ja) 1993-09-22 2006-10-04 ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法
EP0726913A4 (en) 1993-11-10 2000-01-26 Jackson H M Found Military Med CYTOKINES PRODUCED BY NATURAL KILLER CELLS OR T-LYMPHOCYTES
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
NZ309713A (en) 1995-06-07 1999-11-29 Alberta Res Council Oligosaccharides of S pneumoniae serotype 8 and their use in a vaccine
JP4233113B2 (ja) 1995-06-07 2009-03-04 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム 多糖類抗原−キャリア蛋白接合体および遊離キャリア蛋白を有してなるワクチン
JP2000502995A (ja) 1995-12-06 2000-03-14 ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン Ｂリンパ球による抗体放出を刺激する組成物および方法
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
ITPN960013A1 (it) 1996-02-26 1997-08-26 Marcello Piazza Farmaco atto a proteggere l'individuo dal contagio di epatite virale, ecc.
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
DE69739981D1 (de) 1996-10-31 2010-10-14 Human Genome Sciences Inc Streptococcus pneumoniae-Antigene und Impfstoffe
CN1241937A (zh) 1996-11-22 2000-01-19 普罗克特和甘保尔公司 化妆品组合物
ES2156611T3 (es) 1996-12-16 2001-07-01 Nederlanden Staat Metodo para acoplar polisacaridos a proteinas.
US6248334B1 (en) 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
KR19980067137A (ko) 1997-01-31 1998-10-15 박원훈 알긴산염 초미세과립구를 이용한 폐렴구균 감연중에 대한 백신
DE19708537A1 (de) 1997-03-03 1998-09-10 Biotechnolog Forschung Gmbh Neues Oberflächenprotein (SpsA-Protein) von Streptococcus pneumoniae etc.
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
EP0969873B1 (en) 1997-03-27 2006-06-07 Institut Pasteur Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
US6087328A (en) 1997-04-24 2000-07-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine Coupling of unmodified proteins to haloacyl or dihaloacyl derivatized polysaccharides for the preparation of protein-polysaccharide vaccines
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
EP0998557A2 (en) 1997-07-21 2000-05-10 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
US6224880B1 (en) 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
JP2002502882A (ja) 1998-02-12 2002-01-29 アメリカン・サイアナミド・カンパニー インターロイキン−１２とともに処方された肺炎球菌および髄膜炎菌のワクチン
US5985264A (en) 1998-03-05 1999-11-16 The Medical College Of Ohio IL-12 Stimulation of Neonatal immunity
US6645503B1 (en) 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
AU3005499A (en) 1998-03-16 1999-10-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine Induction and enhancement of the immune response to type-2 cell-independent antigens conjugated to lipid or lipid-containing moieties
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
WO2000009075A2 (en) 1998-08-14 2000-02-24 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
ATE446107T1 (de) 1998-08-19 2009-11-15 Baxter Healthcare Sa Immunogenes beta-propionamido-gebundenes polysaccharid-protein konjugat geeignet als impfstoff und hergestellt bei verwendung von n- acryloyliertem polysaccharid
EP1121149A4 (en) 1998-08-31 2002-03-20 Inhibitex Inc IMMUNOTHERAPY METHOD FOR STAPHYLOCOCCAL INFECTIONS INCLUDING DONOR SELECTION AND DONOR STIMULATION
US6692739B1 (en) 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US6585973B1 (en) 1998-10-29 2003-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for preparing solid phase conjugated vaccine
CA2354377C (en) 1998-12-09 2007-04-10 Tatsuji Seki A method for manufacturing glycoproteins having human-type glycosylation
GB9902659D0 (en) 1999-02-05 1999-03-31 Microbiological Res Authority Assay with reduced background
EP1034792A1 (en) 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
EP1035137A1 (en) 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Method for the reductive amination of polysaccharides
GB9906437D0 (en) 1999-03-19 1999-05-12 Smithkline Beecham Biolog Vaccine
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
BRPI0009163B8 (pt) 1999-03-19 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica e vacina que a compreende
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
WO2000062802A2 (en) 1999-04-20 2000-10-26 Smithkline Beecham Biologicals Sa Vaccine comprising rsv antigen and cpg oligonucleotide
CO5241278A1 (es) 1999-04-20 2003-01-31 Glaxosmithkline Biolog Sa Vacuna
JP2002542264A (ja) 1999-04-21 2002-12-10 パウダージェクト ヴァクシンズ，インコーポレイテッド 核酸による免疫化
US6706267B1 (en) 1999-09-14 2004-03-16 Arkion Life Sciences Llc Glucosamine and egg for reducing inflammation
US6569143B2 (en) 1999-10-14 2003-05-27 Becton, Dickinson And Company Method of intradermally injecting substances
US6382204B1 (en) 1999-10-14 2002-05-07 Becton Dickinson And Company Drug delivery system including holder and drug container
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6537552B1 (en) 1999-10-19 2003-03-25 Iowa State University Research Foundation Vaccine adjuvant
DE10012370A1 (de) 2000-03-14 2001-09-27 Chiron Behring Gmbh & Co Adjuvans für Vakzinen
FR2806304B1 (fr) 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
US20030021795A1 (en) 2000-06-14 2003-01-30 Houston Michael E. Use of coiled-coil structural scaffold to generate structure-specific peptides
EG24742A (en) 2000-06-29 2010-07-14 Smithkline Beecham Biolog Vaccine composition.
AUPQ846900A0 (en) 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
US6673905B2 (en) 2000-08-09 2004-01-06 The United States Of America As Represented By The Department Of Health And Human Services Conjugation of biomolecules using Diels-Alder cycloaddition
US6962700B1 (en) 2000-09-13 2005-11-08 Atopix Pharmaceuticals Corporation Method of manufacturing immune globulin
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
FR2816844A1 (fr) 2000-11-17 2002-05-24 Pf Medicament Domaine periplasmique d'une proteine omp d'enterobacterie et son utilisation comme porteur et/ou adjuvant
FR2819724B1 (fr) 2001-01-22 2005-05-13 Inst Necker Moyens pour induire une reponse immune aux antigenes bacteriens polysccharidiques et aux structures proteiques des capsides de virus
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20060110407A1 (en) 2001-12-05 2006-05-25 Shelley Stopera Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection
GB0130215D0 (en) 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
US20030118591A1 (en) 2001-12-21 2003-06-26 Joshua Levy Passive hyperimmune antibody therapy in the treatment of anthrax
US7718375B2 (en) 2002-02-27 2010-05-18 Binax, Inc. Modification of bioassays for detection of antigens characteristic of bacteria that are causative of ear and respiratory infections to eliminate false positive results caused by nasopharyngeal colonization of children
US20030211110A1 (en) 2002-05-07 2003-11-13 Laniado Kiryat Sanz Hospital Pharmaceutical compositions and articles of manufacture useful in reversal of a clinical epiosode of an incurable disease and methods of use thereof
AU2002309259A1 (en) 2002-05-09 2003-11-11 Massimo Porro Improved polysaccharide and glycoconjugate vaccines_____________
KR20050086427A (ko) 2002-11-07 2005-08-30 시너지 아메리카 인코포레이티드 폐렴균의 감염 치료 또는 예방용 조성물 및 방법
WO2004052394A1 (en) 2002-12-06 2004-06-24 Biosynth S.R.L. Broad-spectrum lps based vaccines of unencapsulated strains of haemophilus influenzae and other pathogenic species of gram-negative bacteria
FR2850106B1 (fr) 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
GB0301433D0 (en) 2003-01-22 2003-02-19 Adjuvantix Ltd Protein adjuvant
WO2004097000A2 (en) 2003-04-29 2004-11-11 Purdue Research Foundation Ligand-exchange functional antigens, and use of same in pharmaceutical vaccine compositions
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
AU2004251726B2 (en) 2003-06-23 2010-01-28 Baxalta GmbH Carrier proteins for vaccines
CA2844154C (en) 2003-08-06 2016-12-20 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
US6984492B2 (en) 2003-09-05 2006-01-10 Talecris Biotherapeutics, Inc. Methods and compositions for treating herpes infections
US20050070876A1 (en) 2003-09-26 2005-03-31 Penjet Corporation Method and apparatus for administering a vaccine or other pharmaceutical
US20070134762A1 (en) 2003-12-17 2007-06-14 Arumugham Rasappa G Immunogenic peptide carrier conjugates and methods of producing same
JP4696079B2 (ja) 2003-12-17 2011-06-08 ヤンセン アルツハイマー イミュノセラピー Ａβ免疫原性ペプチド担体結合物およびそれの製造方法
WO2005058968A1 (en) 2003-12-18 2005-06-30 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa A method to make a peptide-carrier conjugate with a high immunogenicity
WO2005060713A2 (en) 2003-12-19 2005-07-07 Inhibitex, Inc. Method of inhibiting candida-related infections using donor selected or donor stimulated immunoglobulin compositions
EP1703887A4 (en) 2003-12-31 2009-10-21 Univ Rochester IMMUNOGENIC POLYPEPTIDES AND CONJUGATES THAT CAN INDUCE ANTIBODIES AGAINST PATHOGENIC AGENTS AND USES THEREOF
NZ530709A (en) 2004-01-21 2006-07-28 Agres Ltd Improved IGA production method
US20050158329A1 (en) 2004-01-21 2005-07-21 Ghosh Swapan K. Novel phytol derived immunoadjuvants and their use in vaccine formulations
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
WO2005120563A2 (en) 2004-06-04 2005-12-22 Pharmexa Inc. Induction of an immune response against streptococcus pneumoniae polysaccharides
CA2472818A1 (en) 2004-06-30 2005-12-30 Institut Pasteur Carbohydrate-phosphorylcholine conjugate molecules and their use in vaccinal, therapeutic and diagnostic applications
US8273357B2 (en) 2004-07-16 2012-09-25 Massachusetts Institute Of Technology Antigen-carbohydrate conjugates
US7718624B2 (en) 2004-09-01 2010-05-18 Sitkovsky Michail V Modulation of immune response and inflammation by targeting hypoxia inducible factors
GB0419846D0 (en) 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
EP1652859A1 (en) * 2004-11-02 2006-05-03 ZLB Behring AG Immunoglobulin fractions
JP2008521870A (ja) 2004-12-02 2008-06-26 ドマンティス リミテッド 抗ｉｌ−１ｒ１単一ドメイン抗体および治療使用
JP2008523804A (ja) 2004-12-16 2008-07-10 ステイヒテイング・トツプ・インステイテユト・フード・アンド・ニユトリシヨン 非病原性の非侵襲性グラム陽性細菌中での複合多糖の異種発現および分泌による、病原性グラム陽性細菌の莢膜多糖の新規効率的製造方法
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
CN101123982B (zh) 2005-01-28 2015-06-17 西北大学 脂质和一氧化二氮组合作为用于增强疫苗功效的佐剂
WO2006084467A1 (en) 2005-02-11 2006-08-17 Ace Biosciences A/S Surface-located streptococcus pneumoniae polypeptides
EP2425854A1 (en) 2005-04-08 2012-03-07 Wyeth LLC Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070009542A1 (en) 2005-07-05 2007-01-11 Galit Levin Method and device for transdermal immunization
CN1899609A (zh) 2005-07-19 2007-01-24 复旦大学附属眼耳鼻喉科医院 肺炎球菌多糖蛋白偶联疫苗及其制备方法
US8354249B2 (en) 2005-08-11 2013-01-15 Omrix Biopharmaceuticals Ltd. Intravenous immunoglobulin composition
CA2620416A1 (en) 2005-08-24 2007-03-01 Novartis Vaccines And Diagnostics S.R.L. Zwitterionization of capsular saccharides
EP1928418B1 (en) 2005-09-30 2011-12-21 Lipoxen Technologies Limited Liposomal vaccine compositions comprising a polysaccharide antigen and a protein adjuvant
US20070231344A1 (en) 2005-10-28 2007-10-04 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
EP1951300B1 (en) 2005-11-04 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Changing th1/th2 balance in split influenza vaccines with adjuvants
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EP1973564B1 (en) 2005-12-22 2016-11-09 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
JP5286089B2 (ja) 2006-01-13 2013-09-11 バクスター・インターナショナル・インコーポレイテッド ポリサッカライドを精製する方法
ES2409844T3 (es) 2006-01-30 2013-06-28 Grifols Therapeutics Inc. Metodo para el tratamiento y la profilaxis de enfermedades relacionadas con la deposicion de amiloide utilizando IgM
CN101024079B (zh) 2006-02-17 2012-02-01 福州昌晖生物工程有限公司 肺炎链球菌多糖-外膜蛋白结合疫苗及制备方法
AU2007237133A1 (en) 2006-02-17 2007-10-18 Novartis Ag Purification of bacterial antigens
KR101711903B1 (ko) 2006-03-17 2017-03-03 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 복합 다가 면역원성 콘쥬게이트의 제조 방법
EP2357001B1 (en) 2006-03-22 2018-03-07 GlaxoSmithKline Biologicals S.A. Regimens for immunisation with meningococcal conjugates
GB0606856D0 (en) 2006-04-05 2006-05-17 Univ Leicester Vaccine compositions
EP2007427A4 (en) 2006-04-11 2012-04-04 Yeda Res & Dev IMPROVED VACCINES COMPRISING PEPTIDE MULTIPLE MEDIA DERIVED FROM HSP60
AU2007284878B2 (en) 2006-08-07 2013-01-17 President And Fellows Of Harvard College Protein matrix vaccines and methods of making and administering such vaccines
JP5081243B2 (ja) 2006-08-17 2012-11-28 ザ ユーエービー リサーチ ファウンデーション 肺炎球菌抗原を被検体における肺炎球菌性肺炎の指標とする方法
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
WO2008039838A2 (en) 2006-09-27 2008-04-03 St. Jude Children's Research Hospital Synthetic streptococcus pneumoniae vaccine
US7597891B2 (en) 2006-12-13 2009-10-06 Simon Michael R Synthesis of human secretory IgA for the treatment of Clostridium difficile associated diseases
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700135D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
GB0703369D0 (en) 2007-02-21 2007-03-28 Health Prot Agency Compositions Comprising Capsular Polysaccharides and Their Use as Vaccines
PT2129693T (pt) 2007-03-23 2017-02-14 Wyeth Llc Processo de purificação abreviado para a produção de polissacáridos capsulares de streptococcus pneumoniae
WO2008119358A2 (en) 2007-03-30 2008-10-09 Ace Biosciences A/S Surface-located streptococcus pneumoniae polypeptides for use in vaccine compositions
EP2167531B1 (en) 2007-05-25 2012-03-21 Novartis AG Streptococcus pneumoniae pilus antigens
CN105267974A (zh) 2007-06-20 2016-01-27 辉瑞爱尔兰制药公司 用于缀合疫苗的经过修饰的多糖
US20100183662A1 (en) 2007-06-26 2010-07-22 Ralph Leon Biemans Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US20100290996A1 (en) 2007-09-10 2010-11-18 Arizona Board Of Regents, For And On Behalf Of Arizona State University Methods and compositions based on culturing microorganisms in low sedimental fluid shear conditions
EP2244695A1 (en) 2007-12-07 2010-11-03 Novartis AG Compositions for inducing immune responses
WO2009106085A1 (en) 2008-02-28 2009-09-03 Nordic Vaccine A/S Vaccine compositions comprising saccharide antigens
WO2009140236A2 (en) 2008-05-12 2009-11-19 Strox Biopharmaceuticals, Llc Staphylococcus aureus-specific antibody preparations
US9125863B2 (en) 2008-05-22 2015-09-08 Children's Medical Center Corporation Synergistic immunogenic fusion protein-polysaccharide conjugate
US20100040601A1 (en) 2008-06-10 2010-02-18 Cantin Edouard M Compositions and methods for treating herpes simplex virus infections and related diseases
EP2313116A1 (en) 2008-08-08 2011-04-27 Intercell AG Improved bacterial polysaccharide-polypeptide conjugate compositions
AU2009323682A1 (en) 2008-12-03 2010-06-10 Protea Vaccine Technologies Ltd. Glutamyl tRNA synthetase (GtS) fragments
EP2385842A1 (en) 2009-01-12 2011-11-16 Novartis AG Cna_b domain antigens in vaccines against gram positive bacteria
SG173173A1 (en) 2009-02-19 2011-08-29 Glaxo Group Ltd Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
WO2010109324A1 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
US20120064104A1 (en) 2009-03-24 2012-03-15 Novartis Ag Combinations including pneumococcal serotype 14 saccharide
US8003112B2 (en) 2009-04-16 2011-08-23 Howard University Meningococcal and pneumococcal conjugate vaccine and method of using same
MX340830B (es) 2009-04-30 2016-07-26 Coley Pharm Group Inc Vacuna neumococica y usos de la misma.
WO2010132686A1 (en) 2009-05-13 2010-11-18 Gliknik, Inc. Methods of using immunoglobulin aggregates
US20120135037A1 (en) 2009-06-01 2012-05-31 Mizel Steven B Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
US20120100172A1 (en) 2009-06-25 2012-04-26 Michael Tal Immunogenic streptococcus pneumoniae peptides and peptide-multimers
MX2012000158A (es) 2009-06-29 2012-06-08 Genocea Biosciences Inc Vacunas y composiciones contra streptococcus pneumoniae.
CN101590224A (zh) 2009-06-30 2009-12-02 广州精达医学科技有限公司 高效14价肺炎球菌结合疫苗
CN102686238A (zh) 2009-09-09 2012-09-19 马特里瓦克斯研究和开发公司 具有改善的免疫原性的蛋白质基质疫苗
WO2011041691A1 (en) 2009-10-02 2011-04-07 University Of Iowa Research Foundation Methods of improving vaccine immunogenicity
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
KR20110068831A (ko) 2009-12-16 2011-06-22 재단법인 전라남도생물산업진흥재단 리포좀 조성물, 그 제조방법, 및 폐렴 백신으로서의 그 용도
US9173954B2 (en) 2009-12-30 2015-11-03 Glaxosmithkline Biologicals Sa Polysaccharide immunogens conjugated to E. coli carrier proteins
CN102834112B (zh) 2010-02-22 2016-02-24 流体科技公司 多糖颗粒疫苗
CN101785857B (zh) 2010-03-05 2012-09-26 成都安特金生物技术有限公司 一种新的肺炎球菌结合疫苗及其制备方法
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
CN102068690A (zh) 2010-12-31 2011-05-25 北京民海生物科技有限公司 多价肺炎球菌荚膜多糖结合疫苗及其制备方法
US20130108619A1 (en) 2011-11-02 2013-05-02 Isaac Melamed Intravenous immunoglobulin processing, diagnostic, and treatment systems and methods
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency

Also Published As

Publication number Publication date
MX370191B (es) 2019-12-04
US20220403008A1 (en) 2022-12-22
IL242156B (en) 2019-01-31
US9969793B2 (en) 2018-05-15
EP3026059A1 (en) 2016-06-01
US20240043503A1 (en) 2024-02-08
AU2015246157A1 (en) 2016-05-12
US20180258159A1 (en) 2018-09-13
US9815886B2 (en) 2017-11-14
US11780906B2 (en) 2023-10-10
US20180086818A1 (en) 2018-03-29
EP4233903A3 (en) 2023-11-29
BR102015027387A2 (pt) 2017-12-05
US9714283B2 (en) 2017-07-25
US20210130441A1 (en) 2021-05-06
US20160114037A1 (en) 2016-04-28
RU2015145033A3 (es) 2019-05-22
RU2015145033A (ru) 2017-05-03
CA2910491A1 (en) 2016-04-28
US10683343B2 (en) 2020-06-16
WO2016069693A1 (en) 2016-05-06
RU2724058C2 (ru) 2020-06-19
AU2021202598A1 (en) 2021-05-27
US9107906B1 (en) 2015-08-18
ZA201707303B (en) 2020-01-29
IL263819B (en) 2021-02-28
AU2015246157B2 (en) 2021-05-20
EP4233903A2 (en) 2023-08-30
AU2021202598B2 (en) 2024-09-19
US20160115221A1 (en) 2016-04-28
US11339206B2 (en) 2022-05-24
IL263819A (en) 2019-01-31
HK1225397A1 (zh) 2017-09-08

Similar Documents

Publication Publication Date Title
MX370191B (es) Composiciones y su uso en el tratamiento de la inmunodeficiencia.
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
JOP20200192A1 (ar) أجسام مضادة لـ tigit
MX2022007522A (es) Anticuerpos anti-cd27.
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
MX2018005720A (es) Anticuerpos pd-l1, fragmento de union al antigeno del mismo, y aplicacion medica de ello.
TN2016000559A1 (en) Monoclonal antibodies against her2 epitope and methods of use thereof
MX2022005253A (es) Anticuerpos neutralizantes de poliomavirus.
EA032929B1 (ru) Нейтрализующее вирус иммунодефицита человека антитело и способы его применения
PH12016501760A1 (en) Anti-mcam antibodies and associated methods of use
EA201792157A1 (ru) Имидазопиразиноны в качестве ингибиторов pde1
MX2017003216A (es) Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2017002093A (es) Terapia con anticuerpos para vih como sustituto de tratamiento.
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
EA201691335A1 (ru) Гексагидрофуропирролы в качестве ингибиторов pde1
EA201792282A1 (ru) Способы лечения заболеваний
IL240241B (en) Antibodies directed to bacillus anthracis protective antigen

Legal Events

Date Code Title Description
FG Grant or registration